Injection site abscess due to the Mycobacterium fortuitum-chelonae - Complex in the immunocompetent host

Infectious Diseases in Clinical Practice

Volumn 7, Issue 1, 1998, Pages 56-60

  Torres R , Jaime R ^a   Rios Fabra, Antonio ^b   Murillo, Jorge ^b   Montecinos, Eda ^b   Caceres, Ana M ^b  

^a Sociedad Medica Clinica Santa Sofia   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN;

ADULT; ARTICLE; BUTTOCK; CASE REPORT; FEMALE; HOSPITAL INFECTION; HUMAN; INJECTION SITE; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; ORAL DRUG ADMINISTRATION; SKIN ABSCESS; SOFT TISSUE INFECTION; UNITED STATES;

EID: 0031886221     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199801000-00012     Document Type: Article

References (35)

1. McFarland E, Kuritzkes D. Clinical features and treatment of infection due to Mycobacterium fortuitum-chelonae complex. In: Remington J, Swartz M, editors. Current clinical topics in infectious diseases. Vol. 13. Boston: Blackwell Scientific Publications; 1993. p. 188-202.
2. Wolinsky E. Mycobacterial diseases other than tuberculosis. Clin Infect Dis 1992;15:1-12.
3. Hand WL, Sandford JP. Mycobacterium fortuitum - a human pathogen. Ann Intern Med 1970;73:971-7.
4. Levy-Frébault V, Grimont F, Grimont P, et al. Deoxyribonucleic acid relatedness study of the Mycobacterium fortuitum-chelonae complex. Int J Syst Bacteriol 1986;36:458-60.
5. Kusunoki S, Ezaki T. Proposal of Mycobacterium peregrinum sp. nov., nom. rev., and elevation of Mycobacterium chelonae subsp. abscessus (Kubica et al.) to species status: Mycobacterium abscessus comb. nov. Int J Syst Bacteriol 1992;42:240-5.
6. Cruz J da Costa. "Mycobacterium fortuitum" um novo bacilo acido resistente patogenico para o homen. Acta Med Rio de Janeiro 1938; 1:297-301.
7. Clapper WE, Withcomb J. Mycobacterium fortuitum abscess at an injection site. JAMA 1967;202:550.
8. Gremillion DH, Mursch SB, Lerner CJ. Injection site abscesses caused by Mycobacterium chelonei. Infect Control 1983;4:25-8.
9. Inman PM, Beck A, Brown AC, et al. Outbreak of injection abscesses due to M. abscessus. Arch Dermatol 1969;100:141-6.
10. Vanderpitte J, Desmyter J, Gatti F Mycobacteria, skins and needles. Lancet 1969;2:691.
11. Canilang B, Armstrong D, Subcutaneous abscesses due to Mycobacterium fortuitum: report of a case. Am Rev Respir Dis 1968;97: 451-2.
12. Beck A. Mycobacterium fortuitum in abscesses of man. J Clin Pathol 1965;18:307-13.
13. Owen H, Smith A, Coultras J. Granulomatous lesions occurring at sites of injections of vaccines and antibiotics. South Med J 1963;56: 949-52.
14. Vandepitte J, Desmyter J, Brochier J, et al. Une nouvelle affection a Mycobacteries: abscès post-injection de M. fortuitum. Ann Soc Belg Med Trop 1962;4:555-7.
15. Limbos P, Bretey J, Jadin J, et al. Sur un cas d'abscès a Mycobacterium fortuitum. Ann Soc Belg Med Trop 1961;2:127-8.
16. Borghans JC, Stanford JL. Mycobacterium chelonei in abscesses after injection of diphtheria-pertussis-tetanus-polio vaccine. Am Rev Respir Dis 1973;107:1-8.
17. Wallace RJ, Musser JM, Hull SI, et al. Diversity and sources of rapidly growing mycobacteria associated with infections following cardiac surgery. J Infect Dis 1989;159:708-16.
18. Nolan C, Hashisaki P, Dundas D. An outbreak of soft-tissue infection due to Mycobacterium fortuitum associated with electromyography. J Infect Dis 1991;163 1150-3.
19. Miller L, Mangione E, Beebe J, et al. Infection with Mycobacterium abscessus associated with intramuscular injection of adrenal cortex extract - Colorado and Wyoming, 1995-1996. MMWR 1996;45:713-5.
20. Camargo D, Saad C, Ruiz F, et al Iatrogenic outbreak of M. chelonae skin abscesses. Epidemiol Infect 1996;117:111-9.
21. Villanueva A, Villanueva R, Acosta B, et al. Report on an outbreak of postinjection abscesses due to Mycobacterium abscessus, including management with surgery and clarithromycin therapy and comparison of strains by random amplified polymorphic DNA polymerase chain reaction. Clin Infect Dis 1997; 24:1147-53.
22. Morris CA, Grant GH, Everall PH, et al. Tuberculoid lymphadenitis due to Mycobacterium chelonei. J Clin Pathol 1973;26:422-6.
23. Alley JW, Rochat R, Smith JD, et al Abscesses in an allergy practice due to Mycobacterium chelonae. Georgia Epidemiol Report 1990; 6:2.
24. Burns DN, Rohatgi PK, Rosenthal R, et al. Disseminated Mycobacterium fortuitum successfully treated with a combination therapy including ciprofloxacin. Am Rev Respir Dis 1990;142:468-70.
25. Levine N, Rothschild JG. Treatment of Mycobacterium chelonae infection with controlled localized heating. J Am Acad Dermatol 1991; 24:867-70.
26. Ausina V, Condom MJ, Mirelis B, et al. In vitro activity of clofazamine against rapidly growing nonchromogenic mycobacteria. Antimicrob Agents Chemother 1986;29:951-2.
27. Wallace RJ, Swenson JM, Silcox VA, et al. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985;152:500-14.
28. Gutknecht DR Treatment of disseminated Mycobacterium chelonae infection with ciprofloxacin. J Am Acad Dermatol 1990; 23:1179-80.
29. Dalovisio JR, Pankey GA, Wallace RJ, et al. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei Rev Infect Dis 1981;3:1068-74.
30. Brown BA, Wallace RJ, Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992;36 180-4.
31. Wallace RJ, Tanner D, Brennan P, Brown B. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 1993;119: 482-6.
32. Swenson JM, Thornsberry C, Silcox VA. Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth macrodilution. Antimicrob Agents Chemother 1982;22:186-92.
33. Eisenberg E, Barza M. Azithromycin and clarithromycin. In: Remington J, Swartz M, editors. Current clinical topics in infectious diseases. Vol. 14. Boston, New York: Blackwell Scientific Publications; 1994. p. 52-79.
34. Wallace RJ, Brown BA, Onyi GO Susceptibilities of Mycobacterium fortuitum biovar fortuitum and two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid Antimicrob Agents Chemother 1991;35:773-5.
35. Franck N, Cabié A, Villette B, et al. Treatment of Mycobacterium/chelonae-induced skin infection with clarithromycin. J Am Acad Dermatol 1993;28:1019-21.